Puma Biotechnology, Inc. growth

Reported trailing growth, forward expectations and three-year compound growth rates.

Trailing growth

Year over year

Revenue: -2.4%
EBITDA: -17.8%
EBIT: -20.8%
EPS: -35.2%
Free cash flow: +72.0%
Operating cash flow: +71.4%

Forward estimates

Revenue: -45.4%
EBITDA: -1.4%
EPS: -23.4%

Three-year CAGR

Revenue: +0.0%
EBITDA: +34.6%
EBIT: +16.3%
Net income: +2396.3%
EPS: +212.1%
Free cash flow: +70.4%

Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.